ReiThera Expands Large-Scale Viral Vector Production Capabilities with Opening of New Manufacturing Facility



New 1,500 m². the facility has obtained operating authorization from AIFA, the Italian Medicines Agency, to allow production scales of up to 3,000 liters;

The new facility will allow ReiThera to consolidate its competitive position as a leading contract development and manufacturing organization (CDMO) specializing in the production of viral vectors

ROME, November 3, 2022 /PRNewswire/ — ReiThera, a biotechnology company dedicated to the development of new technologies, the GMP production and the clinical translation of genetic vaccines and products for advanced therapies, announces today that it has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area in his pharmaceutical laboratory at the Castel Romano Technopole, for the large-scale production of viral vectors for vaccines and gene therapy.

Designed to meet the growing global demand for viral vector production, a sector in which ReiThera represents world-class excellence, the new facility offers maximum flexibility on the processing scale, capable of accommodating GMP productions based on adenovirus (Ad), adeno-associated virus (AAV) and lentivirus from 50 liters up to a maximum of 3,000 liters.

The facility will serve ReiThera’s customer base, which ranges from small biotechnology companies to large multinational pharmaceutical groups. To date, the ReiThera team has successfully developed genetic vaccines against major infectious diseases including Hepatitis C, Malaria, HIV, Respiratory Syncytial Virus, Ebola and Covid 19.

The construction of the new production plant, which covers an area of ​​1500 m², began in May 2020 with more investment 15 million euros by ReiThera. This investment enabled the installation of latest-generation bioreactors with modulated volume capacities of 200, 1,000 and 2,000 litres.

“Thanks to the authorization to operate this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive experience in the engineering and bioprocessing of viral vectors, will be able to support companies engaged in the development of products in the field of vaccines and advanced therapies, from the development of small-scale production processes to commercial-scale production”, said Stefano Collocachief technology officer and co-founder of ReiThera.

About ReiThera Srl

ReiThera Srl is a biotechnology company dedicated to the technological development, GMP manufacturing and clinical translation of genetic vaccines and drugs for advanced therapies. The company’s management and scientific teams have developed a highly innovative technological platform based on simian adenoviral vectors that can be used for vaccine and advanced therapy applications. ReiThera is actively working on the implementation of scalable processes applicable to different viral vectors: AAV, LV, MVA, HSV.

ReiThera is led by an experienced management team who have worked together for many years in previous successful businesses and have longstanding expertise in scalable processes for viral vector manufacturing, supported by a cGMP facility including a filling room and quality control laboratories.

Today, ReiThera offers a wide range of services that include both process development and GMP production of viral vectors and analytical activities, including immunological characterization of biological therapies. ReiThera offers immunosurveillance service capabilities for early drug or vaccine development.

ReiThera has its headquarters, R&D laboratories and GMP facilities in Roma, Italy.

For more information see:

Media contacts:

ReiThera Srl
Stefano CollocaChief Technology Officer
Shaad Cajee, Marketing Manager
[email protected]

MEDISTRAVA Consulting – International Press
Sylvie BerrebiMark Swallow PhD, George Underwood
+44 (0) 203 928 6900
[email protected]


SOURCE ReiThera Srl

Source link


Comments are closed.